Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Income (2018 - 2025)

Ligand Pharmaceuticals' Net Income history spans 14 years, with the latest figure at $44.8 million for Q4 2025.

  • For Q4 2025, Net Income rose 244.06% year-over-year to $44.8 million; the TTM value through Dec 2025 reached $124.5 million, up 500.32%, while the annual FY2025 figure was $124.5 million, 3186.63% up from the prior year.
  • Net Income for Q4 2025 was $44.8 million at Ligand Pharmaceuticals, down from $117.3 million in the prior quarter.
  • Across five years, Net Income topped out at $117.3 million in Q3 2025 and bottomed at -$42.5 million in Q1 2025.
  • The 5-year median for Net Income is -$3.8 million (2021), against an average of $3.2 million.
  • The largest annual shift saw Net Income plummeted 136.03% in 2022 before it soared 244.06% in 2025.
  • A 5-year view of Net Income shows it stood at -$2.2 million in 2021, then tumbled by 32.75% to -$3.0 million in 2022, then skyrocketed by 43.58% to -$1.7 million in 2023, then tumbled by 1767.15% to -$31.1 million in 2024, then skyrocketed by 244.06% to $44.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Net Income are $44.8 million (Q4 2025), $117.3 million (Q3 2025), and $4.8 million (Q2 2025).